SynthesisBMJ open2018
MicroRNA-17 and the prognosis of human carcinomas: a systematic review and meta-analysis.
Synthesis in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis.Disease markers · 2020Pooled it
- Diagnostic value of PPARδ and miRNA-17 expression levels in patients with non-small cell lung cancer.Scientific reports · 2021Trial
- Prognostic impact of miR-17-5p and miR-20a-5p in NSCLC diverge in subgroups according to lymph node status.Frontiers in oncology · 2025Article
- MicroRNA Monitoring in Human Alveolar Macrophages from Patients with Smoking-Related Lung Diseases: A Preliminary Study.Biomedicines · 2024Article
- hnRNP A1 and hnRNP C associate with miR-17 and miR-18 in thyroid cancer cells.FEBS open bio · 2022Article
- High expression of miR-17-5p and miR-20a-5p predicts favorable disease-specific survival in stage I-III colon cancer.Scientific reports · 2022Article
- High expression of miR-17-5p in tumor epithelium is a predictor for poor prognosis for prostate cancer patients.Scientific reports · 2021Article
- Prognostic value of BRAF/MIR-17 signature and B-Raf protein expression in patients with colorectal cancer: A pilot study.Journal of clinical laboratory analysis · 2021Article
- NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.International journal of molecular sciences · 2020Article
- miR‑144 promotes the proliferation and differentiation of bone mesenchymal stem cells by downregulating the expression of SFRP1.Molecular medicine reports · 2019Article
- MicroRNA-17 promotes cell proliferation and migration in human colorectal cancer by downregulating SIK1.Cancer management and research · 2019Article
- Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer.Cancer genomics & proteomicsArticle
- MicroRNAs and Cancer Racial Disparities.Wiley interdisciplinary reviews. RNAReview
Corrections and comments
- Erratum issuedCorrection:2018
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough the role of microRNA-17 (miR-17) has been identified as a tumour biomarker in various studies, its prognostic value in cancers remains unclear. Therefore, we performed a systematic review and meta-analysis to analyse and summarise the relationship between the miR-17 status and clinical outcome in a variety of human cancers.
designSystematic review and meta-analysis. DATA SOURCES: PubMed, Web of Science and Embase from the first year of records to 15 May 2017. OUTCOMES: The patients' survival results were pooled, and pooled HRs with 95% CIs were calculated and used for measuring the strength of association between miR-17 and the prognosis of cancers, including hepatocellular carcinoma, lung cancer, osteosarcoma, glioma, T-cell lymphoblastic lymphoma and colon cancer. Heterogeneity, publication bias and subgroup analysis were also conducted.
resultsA total of 1096 patients were included in this meta-analysis from 12 articles. The results indicated that the increased expression of miR-17 played an unfavourable role in overall survival in various human carcinomas with the HR of 1.342 taking into account the publication bias. In subgroup analysis, HR of ethnicity (non-Asian HR=1.48 and Asian HR=1.40), disease (digestive system HR=1.36 and blood system cancer (HR=2.38) were significant with P<0.05. For the analysis of disease-free survival and recurrence-free survival, the increased expression of miR-17 was associated with unfavourable prognosis (HR=1.40).
conclusionsmiR-17 may be a useful biomarker in predicting the clinical outcome of human cancers, but due to the limitations of the current studies, further verification of the role of miR-17 in human malignancies is urgently needed. PROSPERO REGISTRATION NUMBER: CRD42017065749.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.